Episurf Medical takes the next step in the UK market by the appointment of Ideal Med Ltd as agent
Episurf Medical (Nasdaq: EPIS B) today announces that the company has entered into a Commercial Agency agreement with Ideal Med Ltd for the sale and distribution of the Episealer® Knee and Episealer® Talus technologies for the UK market. Ideal Med, who will act as an agent for Episurf Medical in the UK market, is a manufacturer and distributor of medical technology products, with a focus on patient-specific innovative solutions. Ideal Med’s sales force covers the entire UK.
Episurf Medical is currently allocating additional resources to its Indirect Channel Management strategy, and the company’s current sales force in the UK will expand its geographic focus to include additional markets.
“We are delighted to enter into this partnership with Episurf. We believe that with our experience in personalised devices we will be able to achieve high growth with Episurf’s innovative solutions across the NHS and private sector and look forward to working with Steve and the Episurf team”, says Stewart Fraser, Sales and Marketing Director, Ideal Med Ltd.
“It is exciting to partner with Stewart and the team at Ideal Med in the UK. They have proven sales performance with individualised products and are the perfect partner for us as we accelerate our commercial strategy in the UK”, says Steve Caswell, Head of Sales, OUS, Episurf Medical.
“We are committed to taking the next important steps in the UK market, and we are pleased with entering into this cooperation with Ideal Med, who is an excellent partner for us. The reimbursement process in the UK market is ongoing, and we are aiming at delivering upon our commercial strategy in the UK, with significant progress already in 2022”, says Pål Ryfors, CEO, Episurf Medical.
By this cooperation, Episurf Medical is exiting a previous Agency agreement for the UK market.
For more information, please contact:
Pål Ryfors, CEO, Episurf Medical
Tel:+46 (0) 709 62 36 69
Email: pal.ryfors@episurf.com
About Episurf Medical
Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and individualised treatment alternatives. Episurf Medical’s Episealer® individualised implants and Epiguide® surgical drill guides are developed for treating localised cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.
Tags: